M1 macrophage-derived exosomes inhibit cardiomyocyte proliferation through delivering miR-155
M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this...
Saved in:
Published in | BMC cardiovascular disorders Vol. 24; no. 1; pp. 365 - 11 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
16.07.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo.
M0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-γ (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot.
The results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway.
M1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. |
---|---|
AbstractList | Abstract Background M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo. Methods M0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-γ (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot. Results The results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway. Conclusion M1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo. M0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-γ (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot. The results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway. M1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. Background M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo. Methods M0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-[gamma] (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot. Results The results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway. Conclusion M1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. Keywords: M1 macrophage, Exosomes, Mir-155, Myocardial infarction, Cardiomyocyte proliferation M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo.BACKGROUNDM1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo.M0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-γ (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot.METHODSM0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-γ (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot.The results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway.RESULTSThe results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway.M1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages.CONCLUSIONM1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. BackgroundM1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo.MethodsM0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-γ (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot.ResultsThe results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway.ConclusionM1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in pathophysiological regulation after MI, but the role of M1 macrophage-derived exosomes (M1-Exos) in myocardial regeneration remains unclear. In this study, we explored the impact of M1 macrophage-derived exosomes on cardiomyocytes regeneration in vitro and in vivo. M0 macrophages were induced to differentiate into M1 macrophages with GM-CSF (50 ng/mL) and IFN-[gamma] (20 ng/mL). Then M1-Exos were isolated and co-incubated with cardiomyocytes. Cardiomyocyte proliferation was detected by pH3 or ki67 staining. Quantitative real-time PCR (qPCR) was used to test the level of miR-155 in macrophages, macrophage-derived exosomes and exosome-treated cardiomyocytes. MI model was constructed and LV-miR-155 was injected around the infarct area, the proliferation of cardiomyocytes was counted by pH3 or ki67 staining. The downstream gene and pathway of miR-155 were predicted and verified by dual-luciferase reporter gene assay, qPCR and immunoblotting analysis. IL-6 (50 ng/mL) was added to cardiomyocytes transfected with miR-155 mimics, and the proliferation of cardiomyocytes was calculated by immunofluorescence. The protein expressions of IL-6R, p-JAK2 and p-STAT3 were detected by Western blot. The results showed that M1-Exos suppressed cardiomyocytes proliferation. Meanwhile, miR-155 was highly expressed in M1-Exos and transferred to cardiomyocytes. miR-155 inhibited the proliferation of cardiomyocytes and antagonized the pro-proliferation effect of interleukin 6 (IL-6). Furthermore, miR-155 targeted gene IL-6 receptor (IL-6R) and inhibited the Janus kinase 2(JAK)/Signal transducer and activator of transcription (STAT3) signaling pathway. M1-Exos inhibited cardiomyocyte proliferation by delivering miR-155 and inhibiting the IL-6R/JAK/STAT3 signaling pathway. This study provided new insight and potential treatment strategy for the regulation of myocardial regeneration and cardiac repair by macrophages. |
ArticleNumber | 365 |
Audience | Academic |
Author | Zhang, Zhanyu Liu, Shiming Liu, Weihua He, Xiaoqing Liu, Shan Chen, Junhao Li, Lihuan Dong, Juan Lin, Zhifeng Liu, Qirui Liu, Shaojun |
Author_xml | – sequence: 1 givenname: Xiaoqing surname: He fullname: He, Xiaoqing – sequence: 2 givenname: Shan surname: Liu fullname: Liu, Shan – sequence: 3 givenname: Zhanyu surname: Zhang fullname: Zhang, Zhanyu – sequence: 4 givenname: Qirui surname: Liu fullname: Liu, Qirui – sequence: 5 givenname: Juan surname: Dong fullname: Dong, Juan – sequence: 6 givenname: Zhifeng surname: Lin fullname: Lin, Zhifeng – sequence: 7 givenname: Junhao surname: Chen fullname: Chen, Junhao – sequence: 8 givenname: Lihuan surname: Li fullname: Li, Lihuan – sequence: 9 givenname: Weihua surname: Liu fullname: Liu, Weihua – sequence: 10 givenname: Shaojun surname: Liu fullname: Liu, Shaojun – sequence: 11 givenname: Shiming surname: Liu fullname: Liu, Shiming |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39014329$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAUhSNURB_wB1igSGzYpPgVx16hqqKlUhESgiWybuybjEdJPNiZivn3eGZK6VQIeWHL_s7xvfY5LY6mMGFRvKbknFIl3yfKVMMqwkRFuNK8Is-KEyoaWjEm6dGj9XFxmtKSENoool8Ux1wTKjjTJ8WPz7QcwcawWkCPlcPo79CV-CukMGIq_bTwrZ9LC9H5MG6C3cxYrmIYfIcRZh-mcl7EsO4XpcMhi6Of-nL0Xyta1y-L5x0MCV_dz2fF96uP3y4_Vbdfrm8uL24rW0sxVxSoaiRzRDnNOlAoVce4cARlDdyJFhTTABoBupZQ1QpB6ho5d8w6DpafFTd7XxdgaVbRjxA3JoA3u40QewNx9nZAw5gmbcuVs40UhLTAOisUEVICl1rX2evD3mu1bkd0Fqc5wnBgengy-YXpw52hlNWU8a3Du3uHGH6uMc1m9MniMMCEYZ0MJ4o2jeCNyujbJ-gyrOOU3ypTOv-vriX5S_WQO_BTF_LFdmtqLhShkubCZabO_0Hl4XD0Nken83n_QPDmcacPLf5JRwbYHsj5SCli94BQYrYRNPsImhxBs4ug2Rarnoisn3dByeX44X_S37LD3p4 |
CitedBy_id | crossref_primary_10_1007_s11886_025_02225_8 crossref_primary_10_3389_fcvm_2024_1493290 crossref_primary_10_2147_DDDT_S486816 |
Cites_doi | 10.1002/advs.201900513 10.1007/s00395-020-0781-7 10.1016/j.trsl.2017.10.001 10.1016/j.jhep.2016.01.035 10.1038/nri3800 10.1016/j.cell.2017.08.035 10.1016/S0140-6736(12)60075-0 10.1161/HCQ.0000000000000112 10.3390/ijms21061937 10.1016/j.jacc.2018.08.1038 10.1038/srep22613 10.1016/j.ymthe.2016.09.001 10.2174/1389450118666171031115025 10.1161/CIRCULATIONAHA.109.916346 10.1161/CIRCRESAHA.112.267443 10.1161/CIRCRESAHA.115.307778 10.1161/CIRCULATIONAHA.118.036044 10.1253/circj.CJ-19-1039 10.1093/cvr/cvu059 10.1007/s00395-018-0686-x 10.1126/science.1164680 10.1172/jci.insight.132747 10.1155/2021/9959746 10.1073/pnas.1309810110 10.1016/j.biopha.2018.06.090 10.1161/CIRCULATIONAHA.120.050682 10.1038/cr.2015.110 10.1038/s41569-022-00823-5 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12872-024-03893-0 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1471-2261 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_2290bb38dc76400ba2fc480466a36995 PMC11251235 A801616996 39014329 10_1186_s12872_024_03893_0 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: Student Innovation Program of Guangzhou Medical University grantid: to Shao.L. – fundername: Guangzhou Science and Technology Plan grantid: 202102010101, 202201020220 – fundername: Guangdong Basic and Applied Basic Research Foundation grantid: 2022A1515012474, 2021A1515012546, 2021A1515011364, 2019A1515011214 – fundername: Innovation Team of General Universities in Guangdong Province grantid: 2023KCXTD025 |
GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABUWG ACGFO ACGFS ACIHN ACPRK ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ECGQY EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7QP 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c564t-1a18762d08d92fa8e68f234d0e65a3d4ba829aa9eaafb018b44055e33d2cd3ac3 |
IEDL.DBID | M48 |
ISSN | 1471-2261 |
IngestDate | Wed Aug 27 01:30:27 EDT 2025 Thu Aug 21 18:33:13 EDT 2025 Sun Aug 24 04:02:59 EDT 2025 Sat Jul 26 02:43:49 EDT 2025 Tue Jun 17 22:07:32 EDT 2025 Tue Jun 10 21:04:53 EDT 2025 Mon Jul 21 05:39:33 EDT 2025 Thu Apr 24 23:03:29 EDT 2025 Tue Jul 01 02:38:11 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Cardiomyocyte proliferation Myocardial infarction Mir-155 Exosomes M1 macrophage |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c564t-1a18762d08d92fa8e68f234d0e65a3d4ba829aa9eaafb018b44055e33d2cd3ac3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12872-024-03893-0 |
PMID | 39014329 |
PQID | 3091289560 |
PQPubID | 44077 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_2290bb38dc76400ba2fc480466a36995 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11251235 proquest_miscellaneous_3081774378 proquest_journals_3091289560 gale_infotracmisc_A801616996 gale_infotracacademiconefile_A801616996 pubmed_primary_39014329 crossref_primary_10_1186_s12872_024_03893_0 crossref_citationtrail_10_1186_s12872_024_03893_0 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-07-16 |
PublicationDateYYYYMMDD | 2024-07-16 |
PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-16 day: 16 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC cardiovascular disorders |
PublicationTitleAlternate | BMC Cardiovasc Disord |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | P Tang (3893_CR26) 2018; 106 Y Ma (3893_CR8) 2018; 191 Q Fan (3893_CR11) 2019; 139 MF Corsten (3893_CR23) 2012; 111 Y Fang (3893_CR29) 2013; 110 H Anderson (3893_CR2) 2022; 15 O Bergmann (3893_CR3) 2009; 324 H Deguchi (3893_CR17) 2020; 84 M Nahrendorf (3893_CR9) 2010; 121 J Yap (3893_CR6) 2023; 20 M Horckmans (3893_CR13) 2017; 38 Y Cheng (3893_CR7) 2018; 19 3893_CR12 Y Zhang (3893_CR25) 2016; 6 K Thygesen (3893_CR1) 2018; 72 3893_CR14 3893_CR16 K Fujiu (3893_CR19) 2014; 102 C Wang (3893_CR22) 2017; 25 3893_CR20 AR Pinto (3893_CR5) 2016; 118 S Epelman (3893_CR4) 2015; 15 H Kim (3893_CR21) 2019; 6 S Liu (3893_CR15) 2020; 115 LM Ptaszek (3893_CR18) 2012; 379 C Han (3893_CR27) 2015; 25 3893_CR28 AJ Mouton (3893_CR10) 2018; 113 S Bala (3893_CR24) 2016; 64 |
References_xml | – volume: 6 start-page: 1900513 issue: 20 year: 2019 ident: 3893_CR21 publication-title: ADV SCI doi: 10.1002/advs.201900513 – volume: 115 start-page: 22 issue: 2 year: 2020 ident: 3893_CR15 publication-title: BASIC RES CARDIOL doi: 10.1007/s00395-020-0781-7 – volume: 191 start-page: 15 year: 2018 ident: 3893_CR8 publication-title: TRANSL RES doi: 10.1016/j.trsl.2017.10.001 – volume: 64 start-page: 1378 issue: 6 year: 2016 ident: 3893_CR24 publication-title: J HEPATOL doi: 10.1016/j.jhep.2016.01.035 – volume: 15 start-page: 117 issue: 2 year: 2015 ident: 3893_CR4 publication-title: NAT REV IMMUNOL doi: 10.1038/nri3800 – ident: 3893_CR14 doi: 10.1016/j.cell.2017.08.035 – volume: 379 start-page: 933 issue: 9819 year: 2012 ident: 3893_CR18 publication-title: Lancet doi: 10.1016/S0140-6736(12)60075-0 – volume: 15 start-page: e000112 issue: 10 year: 2022 ident: 3893_CR2 publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/HCQ.0000000000000112 – ident: 3893_CR28 doi: 10.3390/ijms21061937 – volume: 72 start-page: 2231 issue: 18 year: 2018 ident: 3893_CR1 publication-title: J AM COLL CARDIOL doi: 10.1016/j.jacc.2018.08.1038 – volume: 6 start-page: 22613 year: 2016 ident: 3893_CR25 publication-title: SCI REP-UK doi: 10.1038/srep22613 – volume: 25 start-page: 192 issue: 1 year: 2017 ident: 3893_CR22 publication-title: MOL THER doi: 10.1016/j.ymthe.2016.09.001 – volume: 19 start-page: 651 issue: 6 year: 2018 ident: 3893_CR7 publication-title: CURR DRUG TARGETS doi: 10.2174/1389450118666171031115025 – volume: 121 start-page: 2437 issue: 22 year: 2010 ident: 3893_CR9 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.916346 – volume: 111 start-page: 415 issue: 4 year: 2012 ident: 3893_CR23 publication-title: CIRC RES doi: 10.1161/CIRCRESAHA.112.267443 – volume: 118 start-page: 400 issue: 3 year: 2016 ident: 3893_CR5 publication-title: CIRC RES doi: 10.1161/CIRCRESAHA.115.307778 – volume: 139 start-page: 663 issue: 5 year: 2019 ident: 3893_CR11 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.036044 – volume: 84 start-page: 1028 issue: 6 year: 2020 ident: 3893_CR17 publication-title: CIRC J doi: 10.1253/circj.CJ-19-1039 – volume: 102 start-page: 232 issue: 2 year: 2014 ident: 3893_CR19 publication-title: CARDIOVASC RES doi: 10.1093/cvr/cvu059 – volume: 113 start-page: 26 issue: 4 year: 2018 ident: 3893_CR10 publication-title: BASIC RES CARDIOL doi: 10.1007/s00395-018-0686-x – volume: 324 start-page: 98 issue: 5923 year: 2009 ident: 3893_CR3 publication-title: Science doi: 10.1126/science.1164680 – volume: 38 start-page: 187 issue: 3 year: 2017 ident: 3893_CR13 publication-title: EUR HEART J – ident: 3893_CR16 doi: 10.1172/jci.insight.132747 – ident: 3893_CR12 doi: 10.1155/2021/9959746 – volume: 110 start-page: 13416 issue: 33 year: 2013 ident: 3893_CR29 publication-title: P NATL ACAD SCI USA doi: 10.1073/pnas.1309810110 – volume: 106 start-page: 303 year: 2018 ident: 3893_CR26 publication-title: BIOMED PHARMACOTHER doi: 10.1016/j.biopha.2018.06.090 – ident: 3893_CR20 doi: 10.1161/CIRCULATIONAHA.120.050682 – volume: 25 start-page: 1137 issue: 10 year: 2015 ident: 3893_CR27 publication-title: CELL RES doi: 10.1038/cr.2015.110 – volume: 20 start-page: 373 issue: 6 year: 2023 ident: 3893_CR6 publication-title: NAT REV CARDIOL doi: 10.1038/s41569-022-00823-5 |
SSID | ssj0017809 |
Score | 2.4085102 |
Snippet | M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role in... Background M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role... BackgroundM1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a key role... Abstract Background M1 macrophages are closely associated with cardiac injury after myocardial infarction (MI). Increasing evidence shows that exosomes play a... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 365 |
SubjectTerms | Analysis Animals Antibodies Cardiomyocyte proliferation Cardiomyocytes Care and treatment Cell Proliferation - drug effects Cells, Cultured Coculture Techniques Diagnosis Disease Models, Animal Exosomes Exosomes - genetics Exosomes - metabolism Exosomes - transplantation Granulocyte-macrophage colony-stimulating factor Heart Heart attack Heart cells Heart failure Immunoblotting Immunofluorescence Interleukin 6 Interleukin 6 receptors Interleukin-6 - metabolism Interleukins Janus kinase Janus kinase 2 Janus Kinase 2 - metabolism Laboratory animals M1 macrophage Macrophages Macrophages - metabolism Male Mice, Inbred C57BL MicroRNA MicroRNAs - genetics MicroRNAs - metabolism Mir-155 miRNA Myocardial infarction Myocardial Infarction - genetics Myocardial Infarction - metabolism Myocardial Infarction - pathology Myocardial Infarction - physiopathology Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Myocytes, Cardiac - pathology Penicillin Phosphorylation Rats, Sprague-Dawley Receptors, Interleukin-6 - genetics Receptors, Interleukin-6 - metabolism Regeneration Reporter gene Risk factors Signal Transduction Stat3 protein STAT3 Transcription Factor - genetics STAT3 Transcription Factor - metabolism γ-Interferon |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9UwFA4yC3Ejjs86o0QQXEiY5tE0WY7iMAjjQhyYjYQ8uYW57eDtiPPvPUl7L7cIunHbnEKT852cL-3pdxB6yxx1CYgGSUILImwSxNI6ECGEZhEYdBNKtcUXeX4pPl81V3utvnJN2CQPPC3cSdYjd46r4FsJeHOWJS8UnOqk5VLrol4KOW97mJq_H7Sq1ttfZJQ82cAu3DIC-YhkQTlO6kUaKmr9f-7Je0lpWTC5l4HOHqGHM3XEp9MjH6J7sX-M7l_MH8efoO8XFK9tbsm1gk2CBMDWzxhw_DVshnXc4K5fda4bsS8lqOu7wd-NEd_ktj0pTkDAc9seHOJ1LtiAvIbX3VcCdOApujz79O3jOZm7JxDfSDESamne6UKtgmbJqihVYlyEOsrG8iCcVUxbq6O1ydVUOQHcrYmcB-YDt54_Qwf90McXCIfUMJdyDwmqRfBSRS5YbIIKPCjZxgrR7WIaP0uL5w4X16YcMZQ0kwMMOMAUB5i6Qu9399xMwhp_tf6QfbSzzKLY5QJAxcxQMf-CSoXeZQ-bHLrweN7OfyDAJLMIljlVmf-CpazQ8cISQs4vh7cYMXPIbwwHFMLpFRhkhd7shvOduYytj8NttlEU-DZvVYWeT5DaTSm_fBKc6QqpBdgWc16O9N2qCILTwlJ58_J_rNIResBKoLSEymN0MP64ja-AeI3udYmx38B0J7c priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86QXwRv-2cUkHwQcKaj6bpk0xxDGE-iIP7IiFf9RZ22-vayfbfm5Pm1hVhr81paXq-fklOfwehd9QQ0wSggRtec8x1w7EmhcOc85r6gKBLF6stvomTM_51Va7ShtuQyip3MTEGatdb2CM_ZCGxhcVBSNAft78xdI2C09XUQuMuugfUZVDSVa3mBRepZFHvfpSR4nAID6goDlkJA60cw8UiGUXO_v8j843UtCybvJGHjh-hhwlA5keTxh-jO757gu6fpiPyp-jnKck3GhpzrUOowC5Y2B_vcn_VD_3GD3nbrVvTjrmNhaib695ejz7fQvOexk_mkKfmPbnz51C2EbJbvmm_4wAKnqGz4y8_Pp_g1EMB21LwERNNIN65QrqaNlp6IRvKuCu8KDVz3GhJa61rr3VjCiINDwiu9Iw5ah3Tlj1He13f-Zcod01JTQOdJEjNnRXSM0596aRjTorKZ4jsPqayiWAc-lycq7jQkEJNClBBASoqQBUZ-jDfs53oNW6V_gQ6miWBGjte6C9-qeRpCgjsjWHS2UqEAGU0bSyXBRdCM1HXZYbeg4YVOHB4PavTfwhhkkCFpY4koOAgKTJ0sJAMjmeXwzsbUcnxB_XPTDP0dh6GO6GYrfP9JchIElA3q2SGXkwmNU8JtqA4o3WG5MLYFnNejnTtOtKCk4hVWbl_-3u9Qg9odIEKE3GA9saLS_86AKvRvIne8xezJiBK priority: 102 providerName: ProQuest |
Title | M1 macrophage-derived exosomes inhibit cardiomyocyte proliferation through delivering miR-155 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39014329 https://www.proquest.com/docview/3091289560 https://www.proquest.com/docview/3081774378 https://pubmed.ncbi.nlm.nih.gov/PMC11251235 https://doaj.org/article/2290bb38dc76400ba2fc480466a36995 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBZdC2MvY_d57YIHgz0MbdbFsvwwRjNayiBlhAXCYAjd3AQSu0vS0vz7HSlOVrMy9uIH68hYOrdP0tE5CL2lhpgKgAaueMkx1xXHmmQOc85L6gFB5y5GW5yLsxH_Os7He2hb7qidwOWdS7tQT2q0mH24-bX-DAr_KSq8FB-XYGMLisHb4JAujmFYwh-AZyqCog74n1OFQsaQDwIGGQPsINtLNHd-o-OoYj7_v632LbfVDam85aNOH6GHLbhMjzfS8Bjt-foJuj9oj8-fop8Dks51KNo1ATOCHUjftXepv2mWzdwv02k9mZrpKrUxSHW-bux65dPLUNin8htRSdvCPqnzsxDSAZ4vnU-HGADDMzQ6Pfn-5Qy39RWwzQVfYaJJsIUuk66klZZeyIoy7jIvcs0cN1rSUuvSa12ZjEjDAd3lnjFHrWPasudov25q_xKlrsqpqUKVCVJyZ4X0jFOfO-mYk6LwCSLbyVS2TT4eamDMVFyESKE2DFDAABUZoLIEvd_1udyk3vgndT_waEcZ0mbHF83iQrVaqEJye2OYdLYQYLyMppXlMuNCaCbKMk_Qu8BhFcQNfs_q9o4CDDKkyVLHMiBkoBQJOupQglLabvNWRtRWphUDbAbrW8CYCXqzaw49Q6Bb7ZurQCMJIHJWyAS92IjUbkhhe4ozWiZIdoStM-ZuSz2dxJThJOJYlr_67wEeogc0akOBiThC-6vFlX8N-GtleuheMS566KB_cv5t2Iu7GL2oaPAc9n_8Bg4HLfM |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anQS8IO4EBgQJxAOyltiO4zwgtMGmja0VmjZpL8g4tkMrrUlZO6B_it_IcS5lEdLe9lqfVHbO7XN8fD6A1zSP8wKBBil4xgnXBSc6jizhnGfUIYJObF1tMRJ7J_zzaXK6Bn-6uzC-rLKLiXWgtpXx38g3GSY23Bxggv4w-0E8a5Q_Xe0oNBqzOHDLX7hlm7_f_4T6fUPp7s7xxz3SsgoQkwi-ILGOfQSwkbQZLbR0QhaUcRs5kWhmea4lzbTOnNZFHsUy54hpEseYpcYybRj-7w1Y5wy3MgNY394ZfTlanVukMsq6qzlSbM5xyiklmAeJb2THSNRLfzVLwP-54FIy7BdqXsp8u3fhTgtZw63Gxu7Bmivvw81heyj_AL4O43CqPRXYGIMTsWjTP50N3e9qXk3dPJyU40k-WYSmLn2dLiuzXLhw5umCCtcYYNjSBYXWnflCEcyn4XRyRBCGPISTa3m_j2BQVqV7AqEtEpoXnrsizrg1QjrGqUustMxKkboA4u5lKtO2NPfMGmeq3tpIoRoFKFSAqhWgogDerZ6ZNQ09rpTe9jpaSfpm3PUP1fl31fq28i3z85xJa1KBITHXtDBcRlwIzUSWJQG89RpWPmTg9Ixubz7gIn3zLbUlPe5GSRHARk8SXd30hzsbUW2omat_jhHAq9Wwf9KXz5WuuvAyMkacz1IZwOPGpFZL8h-9OKNZALJnbL0190fKybhuRB7X6JglT6-e10u4tXc8PFSH-6ODZ3Cb1u6QklhswGBxfuGeI6xb5C9aXwrh23W7719xYF9P |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=M1+macrophage-derived+exosomes+inhibit+cardiomyocyte+proliferation+through+delivering+miR-155&rft.jtitle=BMC+cardiovascular+disorders&rft.au=He%2C+Xiaoqing&rft.au=Liu%2C+Shan&rft.au=Zhang%2C+Zhanyu&rft.au=Liu%2C+Qirui&rft.date=2024-07-16&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2261&rft.eissn=1471-2261&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12872-024-03893-0&rft.externalDocID=A801616996 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2261&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2261&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2261&client=summon |